EMA adverse event probe, with teeth, may threaten Roche drugs worth $28bn
This article was originally published in Scrip
The European Medicines Agency announced on 23 October that it will begin to investigate Roche’s alleged non-compliance with pharmacovigilance obligations concerning 19 of its most prominent drugs. Some 80,000 adverse events, including over 15,000 deaths reported following the use of Roche drugs in the US have allegedly neither been analysed by Roche to assess whether they need to be reported to European authorities, nor reported to the European authorities. The EMA is concerned that analysis of these events could shift the balance of risk-benefit of drugs approved in the market.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.